DYRK1A and acute lymphoblastic leukemia: Lastly, they demonstrated that DYRK1A, FOXO1, and STAT3 can be effectively targeted by selective and potent small-molecule inhibitors as a novel therapeutic avenue for B-ALL in children with and without T21.